Avery Jeffers, MD
Internal Medicine · Preston, IDNPI 1386083764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 51.9% of the total. 2025 is the largest year on record at $411, more than ten times the $38 reported in 2019. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$991
- Novo Nordisk$213
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$100
- Lilly USA, LLC$93
- Amgen$60
- Biohaven Pharmaceutical Holding Company Ltd.$46
- plus $408 from 17 others
What the payments were for
- Food & beverage$1,912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 52 | $991 |
| Novo Nordisk | 14 | $213 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $100 |
| Lilly USA, LLC | 7 | $93 |
| Amgen | 4 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Abbott | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $28 |
| Pfizer | 2 | $27 |
| Amarin Pharma, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Exact Sciences | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Medtronic | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Innocoll Pharmaceuticals Limited | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$1,912 in reported general payments places this provider in the 90th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 103 | $88,370 |
| JardianceEmpagliflozin | 99 | $87,021 |
| EliquisApixaban | 74 | $77,137 |
| OzempicSemaglutide | 66 | $73,578 |
| MounjaroTirzepatide | 44 | $48,360 |
| TrulicityDulaglutide | 28 | $35,800 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,218 |
| VraylarCariprazine Hcl | 19 | $18,893 |
| LinzessLinaclotide | 31 | $18,034 |
| FarxigaDapagliflozin Propanediol | 22 | $16,207 |
| QuliptaAtogepant | 12 | $14,588 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,642 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $12,219 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $11,542 |
| Spiriva RespimatTiotropium Bromide | 12 | $7,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $93 | $84,15972 claims |
| PfizerEliquis | $27 | $77,13774 claims |
| Novo NordiskOzempic | $213 | $73,57866 claims |
| AbbVieVraylar, Linzess, Qulipta | $991 | $51,51562 claims |
| AstraZenecaFarxiga | $13 | $16,20722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Preston
- Sherwin D'souzaPocatello$543K
- Diana DumitrascuEagle$143K
- Huiling QiBoise$62K
- Aditya SinghPocatello$37K
- Carolyn BridgesBoise$27K
- Susan WachterIdaho Falls$22K
- Ahmed MahmoodIdaho Falls$21K
- Eric BensonPost Falls$19K
- Douglas AndersenPocatello$7K
- Stephen DenagyAmmon$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.